Loading organizations...
Loading organizations...
Innovative biopharmaceutical company developing targeted cancer pro-drugs.
BioSight has raised $40.0M across 2 funding rounds.
BioSight has raised $40.0M in total across 2 funding rounds.
BioSight has raised $40.0M in total across 2 funding rounds.
BioSight's investors include David Sidransky, Arkin Bio Ventures, Biotel, Migdal Insurance, Primera Capital, The Phoenix Insurance Company, Arkin Holdings, Michael Ilan Management & Investments.
BioSight has raised $40.0M across 2 funding rounds. Most recently, it raised $27.0M Series C Extension in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 2, 2020 | $27.0M Series C Extension | David Sidransky | Arkin Bio Ventures, Biotel, Migdal Insurance, Primera Capital, The Phoenix Insurance Company |
| May 16, 2016 | $13.0M Other Equity | Arkin Holdings, Primera Capital | Michael Ilan Management & Investments |